Clementia Pharmaceuticals Культура компании

Mr. Eric Grinstead has been Chief Commercial Officer of Clementia Pharmaceuticals, Inc., since January 29, 2014. Mr. Grinstead served as Senior Vice President of US Commercial Operations at Synageva BioPharma Corp. He joined Clementia from Medical Marketing Economics (MME), the premier value and pricing firm within the biopharmaceutical industry, where he was involved in the development and implementation of value-based pricing and reimbursement strategies for several companies. He served as the Senior Vice President of Commercial and Business Operations at Synageva BioPharma Corp. since July 2009. Mr. Grinstead served as the Senior Vice President of Corporate and Business Operations at Synageva BioPharma Corp., where he was responsible for corporate and business operations. Mr. Grinstead served as Senior Vice President of Government and Business Affairs of Synageva BioPharma Corp. since October 20, 2009. Mr. Grinstead served as Vice President of United States Access Services and Commercial Operations at Alexion Pharmaceuticals, Inc., since September 2007. His responsibilities included strategic and operational responsibility for the pricing, policy, health economics, distribution, national accounts, payor and channel segments, case management services and other access programs and functions in the United States. He served as an Executive Director of US Access Services at Alexion from September 2006 to September 2007. Mr. Grinstead served as Senior Director of Patient and Product Services at Genzyme Corporation, where he led Genzyme's distribution, collections, case management, customer service and national accounts efforts for Genzyme's LSD Division from January 2005 to September 2006. From July 1998 to January 2005, Mr. Grinstead held a number of commercial positions for Amgen including State Reimbursement and Strategic Alliances Manager and Marketing and Value-Access Associate Director for the Inflammatory and Renal Business Units. He worked at GlaxoSmithKline as a Salesman, Sales Manager and State Lobbyist until when he joined Amgen in 1998. He has over 20 years of experience in commercial strategy, operations, government affairs and reimbursement at companies such as Genzyme and Amgen. Mr. Grinstead served as President of the Safety Net Foundation and the Complement Foundation, two not-for-profit entities that provided drugs at no cost to qualified individuals. Mr. Grinstead holds a B.A. in Religious Studies from Westmont University in Santa Barbara, CA.

Mr. Jeffery Packman, also known as Jeff, has been the Chief Development Officer of Clementia Pharmaceuticals, Inc. since November 2013. Mr. Packman served as a Vice President of Drug Development Operations at FoldRx Pharmaceuticals, Inc. He is responsible for advancing FoldRx's drug candidates into and through clinical development. He served as the Senior Director of Drug Development Operations of FoldRx Pharmaceuticals, Inc. He has over 13 years of international experience in drug development and operations management. Prior to joining FoldRx, Mr. Packman headed Drug Development Operations and Project and Alliance Management at Oscient Pharmaceuticals. At Oscient, he served as Project Leader for its two clinical development candidates and was responsible for building and directing all operational activities for Oscient's clinical development programs. Before joining Oscient Pharmaceuticals, Mr. Packman served as Associate Director of Worldwide Business Operations for the Regulatory Affairs division of PAREXEL International Corp., a multi-national contract research organization serving the pharmaceutical and biotechnology industries. At PAREXEL, Mr. Packman was responsible for directing the worldwide operations of two groups within the Regulatory Affairs function, Regulatory Operations and Business Operations. Mr. Packman received a Bachelor's in Biology from Colby College and a Master's of Business Administration with Highest Honors from the F.W. Olin Graduate School of Business Administration at Babson College.

Mr. Michael Singer, CGA has been the CFO & Corporate Secretary of Clementia Pharmaceuticals, Inc. since March 2015. Mr. Singer served as the Chief Financial Officer of Bedrocan Cannabis Corp. until June 2015. Mr. Singer served as a Consultant of Thallion Pharmaceuticals Inc. from July 1, 2013 to September 30, 2013 and served as its Chief Financial Officer & Corporate Secretary from March 14, 2007 to July 1, 2013. Mr. Singer served as an Executive Director of Finance at Caprion Pharmaceuticals, Inc. since February 2000 and served as its Vice president of Finance, Treasurer and Secretary. Prior to joining Caprion, he served as a Manager of BDO Dunwoody. He is a Pharmaceutical industry Chief Financial Officer and consultant with senior level experience in both public and private life science and innovative technology companies. During his eleven years in public practice, he specialized in audit, taxation and client relations. He has been Chairman of Aurora Cannabis Inc. since November 29, 2016. He served as the Chairman of Warnex Inc. since April 2012 until July 2014 and served as its Independent Director since June 2011 until July 2014. He has been an Independent Director at Aurora Cannabis Inc., since May 20, 2016. He served as an Independent Director at Diagnos Inc. from July 23, 2014 to June 1, 2016. Mr. Singer received a B.Comm in Finance and Accounting from Concordia University, a degree in Public Accountancy from McGill University Faculty of Graduate Studies and holds a Certified General Accountant designation from the Ordre des CGA du Qu???bec.